

## **Fate Therapeutics to Present at Upcoming Investor Conferences**

SAN DIEGO, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Scott Wolchko, President and Chief Executive Officer, will be presenting at three upcoming investor conferences in September:

- | **2017 Wells Fargo Healthcare Conference** at 8:15 a.m. ET on Thursday, September 7, 2017 in Boston, MA.
- | **Cantor Fitzgerald Global Healthcare Conference** at 10:20 a.m. ET on Tuesday, September 26, 2017 in New York, NY.
- | **Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology** at 10:00 a.m. ET on Thursday, September 28, 2017 in New York, NY.

Live webcasts of the presentations will be available through the investor relations section of the Company's website at [www.fatetherapeutics.com](http://www.fatetherapeutics.com). Following the live webcasts, archived replays of each presentation will be available on the Company's website for 30 days after the respective conference.

### **About Fate Therapeutics, Inc.**

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company's hematopoietic cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf product candidates derived from engineered induced pluripotent cell lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients undergoing hematopoietic cell transplantation and to promote immune tolerance in patients with autoimmune disease. Its adoptive cell therapy programs are based on the Company's novel *ex vivo* cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit [www.fatetherapeutics.com](http://www.fatetherapeutics.com).

#### Contact:

Christina Tartaglia  
Stern Investor Relations, Inc.  
212.362.1200  
[christina@sternir.com](mailto:christina@sternir.com)